ALEC — Alector, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1653087 ·
Last close
$1.92
Market Cap
$214.38M
52W High
$3.40
52W Low
$1.09
ADV30
1,456,501
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,320,000 | — | -24,393,000 | -22,990,000 | 202,855,000 | 59,915,000 | 212,825,000 |
| Mar 2026 | 1,046,000 | — | -24,919,000 | -22,930,000 | 239,916,000 | 76,962,000 | 229,534,000 |
| Dec 2025 | 6,237,000 | — | -39,566,000 | -37,267,000 | 293,237,000 | 65,802,000 | 262,588,000 |
| Sep 2025 | 3,260,000 | — | -37,608,000 | -34,667,000 | 335,285,000 | 76,503,000 | 277,573,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,232,000
Investing CF
$153,208,000
Financing CF
$20,168,000
CapEx
$-170,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.10
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,017,976,000
Inventory
—
Receivables
—
ST Investments
$112,883,000
EBIT TTM
$-126,486,000
Pretax Income TTM
$-117,556,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$13,863,000
EBITDA
$-119,029,000
Free Cash Flow
$-107,252,496
Enterprise Value
$98,905,808
Total Cash
$172,798,000
Total Debt
$32,758,000
Shares Out
111,656,919
Trailing EPS
$-1.09
Book Value
$-0.09
ROE
-385.1%
ROA
-27.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 21,045,000 | -156,007,000 | -142,929,000 | 293,237,000 | 262,588,000 | 30,649,000 | -184,031,000 |
| Dec 2024 | 100,558,000 | -144,997,000 | -119,049,000 | 468,303,000 | 341,503,000 | 126,800,000 | -229,905,000 |
| Dec 2023 | 97,062,000 | -151,740,000 | -130,391,000 | 621,827,000 | 487,669,000 | 134,158,000 | -184,162,000 |
| Dec 2022 | 133,617,000 | -137,834,000 | -133,310,000 | 787,648,000 | 573,206,000 | 214,442,000 | -20,329,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.75
Max Pain — expiry 2026-10-16
max pain strike: $1.50 · spot: $1.92 · call oi: 3,564 · put oi: 245
Expected Move to 2026-10-16:
±$0.35
(18.23%) —
implied range
$1.57 –
$2.27
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | $216.74M | $2.69 | — |
| AVXL | ANAVEX LIFE SCIENCES CORP. | $217.84M | $2.35 | — |
| CGEN | COMPUGEN LTD | $220.71M | $2.33 | — |
| CMPX | Compass Therapeutics, Inc. | $199.90M | $1.11 | — |
| CRDL | Cardiol Therapeutics Inc. | $197.43M | $1.69 | — |
News headlines (Yahoo Finance, 1h cache)
Alector to Participate in Upcoming Healthcare Conferences
2026-09-03 20:05 · Yahoo
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-06 20:05 · Yahoo
GSK ends brain drug alliance with Alector
2026-07-09 11:45 · Yahoo
Alector (ALEC) Stock Faces Mixed Analyst Target Changes On Tau Therapy Readthrough
2026-06-19 00:18 · Yahoo
How The Alector (ALEC) Investment Story Is Shifting With Tau Readthroughs And BBB Shuttle Focus
2026-05-19 04:34 · Yahoo
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
2026-05-07 14:00 · Yahoo
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-07 20:05 · Yahoo
Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 23:05 · Yahoo
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis
2026-04-29 20:05 · Yahoo
How The Alector (ALEC) Narrative Is Shifting Toward BBB Shuttle Programs And Execution Risk
2026-04-30 12:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.